Literature DB >> 31504816

Molecular correlates of cerebellar mutism syndrome in medulloblastoma.

Rashad Jabarkheel1, Nisreen Amayiri2,3, Derek Yecies1, Yuhao Huang1, Sebastian Toescu4, Liana Nobre3, Donald J Mabbott3,5,6, Sniya V Sudhakar7, Prateek Malik7, Suzanne Laughlin8, Maisa Swaidan9, Maysa Al Hussaini10, Awni Musharbash11, Geeta Chacko12, Leni G Mathew13, Paul G Fisher14, Darren Hargrave4, Ute Bartels1, Uri Tabori1, Stefan M Pfister15, Kristian Aquilina16, Michael D Taylor17,18,19, Gerald A Grant1, Eric Bouffet3, Kshitij Mankad20, Kristen W Yeom21, Vijay Ramaswamy3,18,19.   

Abstract

BACKGROUND: Cerebellar mutism syndrome (CMS) is a common complication following resection of posterior fossa tumors, most commonly after surgery for medulloblastoma. Medulloblastoma subgroups have historically been treated as a single entity when assessing CMS risk; however, recent studies highlighting their clinical heterogeneity suggest the need for subgroup-specific analysis. Here, we examine a large international multicenter cohort of molecularly characterized medulloblastoma patients to assess predictors of CMS.
METHODS: We assembled a cohort of 370 molecularly characterized medulloblastoma subjects with available neuroimaging from 5 sites globally, including Great Ormond Street Hospital, Christian Medical College and Hospital, the Hospital for Sick Children, King Hussein Cancer Center, and Lucile Packard Children's Hospital. Age at diagnosis, sex, tumor volume, and CMS development were assessed in addition to molecular subgroup.
RESULTS: Overall, 23.8% of patients developed CMS. CMS patients were younger (mean difference -2.05 years ± 0.50, P = 0.0218) and had larger tumors (mean difference 10.25 cm3 ± 4.60, P = 0.0010) that were more often midline (odds ratio [OR] = 5.72, P < 0.0001). In a multivariable analysis adjusting for age, sex, midline location, and tumor volume, Wingless (adjusted OR = 4.91, P = 0.0063), Group 3 (adjusted OR = 5.56, P = 0.0022), and Group 4 (adjusted OR = 8.57 P = 9.1 × 10-5) tumors were found to be independently associated with higher risk of CMS compared with sonic hedgehog tumors.
CONCLUSIONS: Medulloblastoma subgroup is a very strong predictor of CMS development, independent of tumor volume and midline location. These findings have significant implications for management of both the tumor and CMS.
© The Author(s) 2019. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  cerebellar affective disorder; cerebellar mutism; medulloblastoma; posterior fossa syndrome; postoperative cerebellar mutism

Year:  2020        PMID: 31504816      PMCID: PMC7442348          DOI: 10.1093/neuonc/noz158

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  33 in total

1.  Drug induced arousal from the permanent vegetative state.

Authors:  Ralf Clauss; Wally Nel
Journal:  NeuroRehabilitation       Date:  2006       Impact factor: 2.138

2.  Subgroup-specific localization of human medulloblastoma based on pre-operative MRI.

Authors:  Annika K Wefers; Monika Warmuth-Metz; Julia Pöschl; André O von Bueren; Camelia-Maria Monoranu; Klaus Seelos; Aurelia Peraud; Jörg-Christian Tonn; Arend Koch; Torsten Pietsch; Christel Herold-Mende; Christian Mawrin; Antoinette Schouten-van Meeteren; Dannis van Vuurden; Katja von Hoff; Stefan Rutkowski; Stefan M Pfister; Marcel Kool; Ulrich Schüller
Journal:  Acta Neuropathol       Date:  2014-04-04       Impact factor: 17.088

3.  Duration of the pre-diagnostic interval in medulloblastoma is subgroup dependent.

Authors:  Vijay Ramaswamy; Marc Remke; David Shih; Xin Wang; Paul A Northcott; Claudia C Faria; Charles Raybaud; Uri Tabori; Cynthia Hawkins; James Rutka; Michael D Taylor; Eric Bouffet
Journal:  Pediatr Blood Cancer       Date:  2014-02-25       Impact factor: 3.167

4.  Preoperative chemotherapy in children with high-risk medulloblastomas: a feasibility study.

Authors:  Jacques Grill; Arielle Lellouch-Tubiana; Selma Elouahdani; Alain Pierre-Kahn; Michel Zerah; Dominique Renier; Dominique Valteau-Couanet; Olivier Hartmann; Chantal Kalifa; Christian Sainte-Rose
Journal:  J Neurosurg       Date:  2005-10       Impact factor: 5.115

5.  Incidence and severity of postoperative cerebellar mutism syndrome in children with medulloblastoma: a prospective study by the Children's Oncology Group.

Authors:  Patricia L Robertson; Karin M Muraszko; Emiko J Holmes; Richard Sposto; Roger J Packer; Amar Gajjar; Mark S Dias; Jeffrey C Allen
Journal:  J Neurosurg       Date:  2006-12       Impact factor: 5.115

6.  Cerebellar mutism after posterior fossa tumor resection in children: a multicenter international retrospective study to determine possible modifiable factors.

Authors:  Bryan Renne; Julia Radic; Deepak Agrawal; Brittany Albrecht; Christopher M Bonfield; Gesa Cohrs; Taylor Davis; Ashok Gupta; Andrea L O Hebb; Maria Lamberti-Pasculli; Friederike Knerlich-Lukoschus; Spencer Lindsay; P Daniel McNeely; Shibu Pillai; Hitesh Inder Singh Rai; Katherine D Sborov; Aleksander Vitali; Simon Walling; Peter Woerdeman; Wihasto Suryaningtyas; Douglas Cochrane; Ash Singhal; Paul Steinbok
Journal:  Childs Nerv Syst       Date:  2019-01-18       Impact factor: 1.475

7.  Medulloblastoma subgroup-specific outcomes in irradiated children: who are the true high-risk patients?

Authors:  Vijay Ramaswamy; Marc Remke; Jennifer Adamski; Ute Bartels; Uri Tabori; Xin Wang; Annie Huang; Cynthia Hawkins; Donald Mabbott; Normand Laperriere; Michael D Taylor; Eric Bouffet
Journal:  Neuro Oncol       Date:  2015-01-20       Impact factor: 12.300

8.  Akinetic mutism after fourth ventricle choroid plexus papilloma: treatment with a dopamine agonist.

Authors:  H Caner; N Altinörs; S Benli; T Calişaneller; A Albayrak
Journal:  Surg Neurol       Date:  1999-02

9.  Proximal dentatothalamocortical tract involvement in posterior fossa syndrome.

Authors:  E Brannon Morris; Nicholas S Phillips; Fred H Laningham; Zoltan Patay; Amar Gajjar; Dana Wallace; Frederick Boop; Robert Sanford; Kirsten K Ness; Robert J Ogg
Journal:  Brain       Date:  2009-10-05       Impact factor: 13.501

10.  Resolving medulloblastoma cellular architecture by single-cell genomics.

Authors:  Volker Hovestadt; Kyle S Smith; Laure Bihannic; Mariella G Filbin; McKenzie L Shaw; Alicia Baumgartner; John C DeWitt; Andrew Groves; Lisa Mayr; Hannah R Weisman; Alyssa R Richman; Marni E Shore; Liliana Goumnerova; Celeste Rosencrance; Robert A Carter; Timothy N Phoenix; Jennifer L Hadley; Yiai Tong; Jim Houston; Richard A Ashmun; Michael DeCuypere; Tanvi Sharma; Diane Flasch; Antonina Silkov; Keith L Ligon; Scott L Pomeroy; Miguel N Rivera; Orit Rozenblatt-Rosen; Jessica M Rusert; Robert J Wechsler-Reya; Xiao-Nan Li; Andreas Peyrl; Johannes Gojo; Dominik Kirchhofer; Daniela Lötsch; Thomas Czech; Christian Dorfer; Christine Haberler; Rene Geyeregger; Angela Halfmann; Charles Gawad; John Easton; Stefan M Pfister; Aviv Regev; Amar Gajjar; Brent A Orr; Irene Slavc; Giles W Robinson; Bradley E Bernstein; Mario L Suvà; Paul A Northcott
Journal:  Nature       Date:  2019-07-24       Impact factor: 49.962

View more
  7 in total

1.  Conversations on mutism: risk stratification for cerebellar mutism based on medulloblastoma subtype.

Authors:  Jeffrey B Russ; William A Weiss
Journal:  Neuro Oncol       Date:  2020-02-20       Impact factor: 12.300

2.  Less treatment for Wing less medulloblastoma: germline data re-emphasize this.

Authors:  Anirban Das; Vijay Ramaswamy
Journal:  Neuro Oncol       Date:  2020-01-11       Impact factor: 12.300

3.  Male Predisposition in Cerebellar Mutism Syndrome: a Cohort Study.

Authors:  Wei Yang; Ming Ge; Kaiyi Zhu; Jiashu Chen; Ping Yang; Yingjie Cai; XiaoJiao Peng; Jia Wang; Hailang Sun; Yuanqi Ji; Fengmao Zhao; Hong Zhang
Journal:  Cerebellum       Date:  2022-07-23       Impact factor: 3.648

Review 4.  Functional Approaches to the Surgery of Brain Gliomas.

Authors:  Davide Giampiccolo; Sonia Nunes; Luigi Cattaneo; Francesco Sala
Journal:  Adv Tech Stand Neurosurg       Date:  2022

5.  MRI Radiogenomics of Pediatric Medulloblastoma: A Multicenter Study.

Authors:  Michael Zhang; Samuel W Wong; Jason N Wright; Matthias W Wagner; Sebastian Toescu; Michelle Han; Lydia T Tam; Quan Zhou; Saman S Ahmadian; Katie Shpanskaya; Seth Lummus; Hollie Lai; Azam Eghbal; Alireza Radmanesh; Jordan Nemelka; Stephen Harward; Michael Malinzak; Suzanne Laughlin; Sébastien Perreault; Kristina R M Braun; Robert M Lober; Yoon Jae Cho; Birgit Ertl-Wagner; Chang Y Ho; Kshitij Mankad; Hannes Vogel; Samuel H Cheshier; Thomas S Jacques; Kristian Aquilina; Paul G Fisher; Michael Taylor; Tina Poussaint; Nicholas A Vitanza; Gerald A Grant; Stefan Pfister; Eric Thompson; Alok Jaju; Vijay Ramaswamy; Kristen W Yeom
Journal:  Radiology       Date:  2022-04-19       Impact factor: 29.146

6.  Bridging the treatment gap in infant medulloblastoma: molecularly informed outcomes of a globally feasible regimen.

Authors:  Lorena V Baroni; Claudia Sampor; Adriana Gonzalez; Fabiana Lubieniecki; Gabriela Lamas; Carlos Rugilo; Ute Bartels; Ayala Heled; Kyle S Smith; Paul A Northcott; Eric Bouffet; Daniel Alderete; Vijay Ramaswamy
Journal:  Neuro Oncol       Date:  2020-12-18       Impact factor: 12.300

7.  The Clinical and Prognostic Impact of the Choice of Surgical Approach to Fourth Ventricular Tumors in a Single-Center, Single-Surgeon Cohort of 92 Consecutive Pediatric Patients.

Authors:  Nicola Onorini; Pietro Spennato; Valentina Orlando; Fabio Savoia; Camilla Calì; Carmela Russo; Lucia De Martino; Maria Serena de Santi; Giuseppe Mirone; Claudio Ruggiero; Lucia Quaglietta; Giuseppe Cinalli
Journal:  Front Oncol       Date:  2022-02-24       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.